drugset / Trial / NCT05408221

the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular Carcinoma

NCT05408221

Phase 2/3 Recruiting 576 enrolled Shandong New Time Pharmaceutical Co., LTD
RandomizedParallel-groupQuadruple-blindTreatment

Summary

There are two studies included in this protocol. One is an open-label Phase Ⅱ study . The other is a multi-center, double-blind, randomized, phase III study .

Timeline

Start
2022-11-11
Primary completion
2025-08-01
Completion
2026-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject F520 Monoclonal antibody Intravenous
Background Lenvatinib Small molecule Oral